Terms: = Lung cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
20 results:
1. Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylhä C; Marklund L; Näsman A; Sivars L; Dalianis T
Oral Oncol; 2024 Apr; 151():106749. PubMed ID: 38461771
[TBL] [Abstract] [Full Text] [Related]
2. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
3. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract] [Full Text] [Related]
4. Malignant mesothelioma in situ: morphologic features and clinical outcome.
Churg A; Galateau-Salle F; Roden AC; Attanoos R; von der Thusen JH; Tsao MS; Chang N; De Perrot M; Dacic S
Mod Pathol; 2020 Feb; 33(2):297-302. PubMed ID: 31375770
[TBL] [Abstract] [Full Text] [Related]
5. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract] [Full Text] [Related]
6. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine.
Roulois D; Deshayes S; Guilly MN; Nader JS; Liddell C; Robard M; Hulin P; Ouacher A; Le Martelot V; Fonteneau JF; Grégoire M; Blanquart C; Pouliquen DL
Oncotarget; 2016 Jun; 7(23):34664-87. PubMed ID: 27129173
[TBL] [Abstract] [Full Text] [Related]
8. ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer.
Schlienger S; Campbell S; Pasquin S; Gaboury L; Claing A
Oncotarget; 2016 Mar; 7(13):15811-27. PubMed ID: 26908458
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic significance of BAP1, NF2, and cdkn2a in malignant peritoneal mesothelioma.
Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and expression of mutant P53, p16, and Smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract] [Full Text] [Related]
11. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract] [Full Text] [Related]
12. ASAP3 expression in non-small cell lung cancer: association with cancer development and patients' clinical outcome.
Fan C; Tian Y; Miao Y; Lin X; Zhang X; Jiang G; Luan L; Wang E
Tumour Biol; 2014 Feb; 35(2):1489-94. PubMed ID: 24078447
[TBL] [Abstract] [Full Text] [Related]
13. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract] [Full Text] [Related]
14. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Katayama H; Hiraki A; Fujiwara K; Matsuo K; Maeda T; Chikamori K; Kishino D; Tajima K; Ueoka H; Aoe K
Asian Pac J Cancer Prev; 2007; 8(2):221-4. PubMed ID: 17696735
[TBL] [Abstract] [Full Text] [Related]
15. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study.
Abdulkader I; Sánchez L; Cameselle-Teijeiro J; Gude F; Chávez JE; López-López R; Forteza J; Fraga M
Oncol Rep; 2005 Dec; 14(6):1527-31. PubMed ID: 16273250
[TBL] [Abstract] [Full Text] [Related]
16. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract] [Full Text] [Related]
17. Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.
Igarashi T; Jiang SX; Kameya T; Asamura H; Sato Y; Nagai K; Okayasu I
Mod Pathol; 2004 Oct; 17(10):1259-67. PubMed ID: 15154011
[TBL] [Abstract] [Full Text] [Related]
18. clinical significance of p16ink4a and retinoblastoma proteins in non-small-cell lung carcinoma.
Akin H; Yilmazbayhan D; Kiliçaslan Z; Dilege S; Doğan O; Toker A; Kalayci G
Lung Cancer; 2002 Dec; 38(3):253-60. PubMed ID: 12445746
[TBL] [Abstract] [Full Text] [Related]
19. Predictive value of expression of p16ink4a, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers.
Hommura F; Dosaka-Akita H; Kinoshita I; Mishina T; Hiroumi H; Ogura S; Katoh H; Kawakami Y
Br J Cancer; 1999 Oct; 81(4):696-701. PubMed ID: 10574258
[TBL] [Abstract] [Full Text] [Related]
20. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
Mishina T; Dosaka-Akita H; Kinoshita I; Hommura F; Morikawa T; Katoh H; Kawakami Y
Br J Cancer; 1999 Jun; 80(8):1289-95. PubMed ID: 10376986
[TBL] [Abstract] [Full Text] [Related]
